Research institution
British Columbia Cancer Agency Clinical Trials
Studies where British Columbia Cancer Agency is the lead sponsor: what is enrolling now, by phase, condition and country.
In numbers
Open to volunteers: recruiting, not yet recruiting or enrolling by invitation. Active adds studies under way that have stopped recruiting.
Open to volunteers
All 30Cancer
Evidence Development in Cancer Treatment - Real World: PREDiCTrw
This pilot clinical trial aims to assess the real world quality of life and survival of patients treated with therapy that has preliminary evidence of efficacy but uncertainty of the magnitude of clinical benefit or cost…
- Trial name
- NCT06242912
- Testing
- QOL - quality of life, Radiographic or laboratory evaluation
- Where
- Canada
- Volunteers
- 100 people
- Sponsor
- British Columbia Cancer Agency
EGFR Activating Mutation, Leptomeningeal Metastasis
CSF Analysis in EGFR Mutant Non-Small Cell Lung Cancer With Leptomeningeal Disease
Leptomeningeal disease is malignant seeding of the leptomeninges and presents with a variety of symptoms frequently impacting quality of life.
- Conditions
- EGFR Activating Mutation, Leptomeningeal Metastasis, Non Small Cell Lung Cancer
- Trial name
- NCT05257967
- Testing
- Lumbar puncture and Phlebotomy
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- British Columbia Cancer Agency
Cancer
PRecision Oncology Evidence Development in Cancer Treatment - Clinical: PREDiCTc
This pilot clinical trial aims to assess the real world quality of life and survival of patients treated with targeted therapy that has preliminary evidence of efficacy in subjects with advanced rare cancers or cancer harbouring…
- Trial name
- PREDiCTc (NCT04814095)
- Testing
- QOL, CT imaging
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- British Columbia Cancer Agency
B-Cell Leukemia, Non-Hodgkin's Lymphoma
CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies
This is a phase I dose-finding trial of an autologous CD22 targeting chimeric antigen receptor (CAR)-T cell product, called CLIC-2201, for participants with relapsed/refractory B cell malignancies.
- Conditions
- B-Cell Leukemia, Non-Hodgkin's Lymphoma, B-cell Acute Lymphoblastic Leukemia, Diffuse Large B Cell Lymphoma
- Trial name
- NCT06208735
- Testing
- CLIC-2201
- Where
- 7 sites in Canada
- Volunteers
- 24 people
- Sponsor
- British Columbia Cancer Agency
Orbital Lymphoma
Radiotherapy 12Gy in 6 Fractions For Orbital Lymphoma
Current standard RT doses (24-25Gy) provide excellent disease control for patients with indolent B-cell orbital lymphoma, but can cause significant late toxicities.
- Trial name
- NCT07210749
- Testing
- External Beam Radiation Therapy
- Where
- Canada
- Volunteers
- 36 people
- Sponsor
- British Columbia Cancer Agency
Neuroendocrine Tumors, NET, Pheochromocytoma/Paraganglioma
A Comparison of [68Ga]DOTATATE and [18F]AmBF3TATE for the Staging and Assessment of Neuroendocrine Malignancies
Neuroendocrine tumours (NETs) are generally slow growing, but some can be aggressive and resistant to treatment. Compared to healthy cells, the surface of these tumor cells has a greater number of molecules called somatostatin…
- Conditions
- Neuroendocrine Tumors, NET, Pheochromocytoma/Paraganglioma, SSTR-expressing Tumors, Medullary Thyroid Carcinoma
- Trial name
- NET-COMPARE (NCT07621146)
- Testing
- 68Ga-DOTATATE PET/CT, 18F-AmBF3-TATE PET/CT
- Where
- Canada
- Volunteers
- 60 people
- Sponsor
- British Columbia Cancer Agency
Diffuse Large B-cell Lymphoma, Multiple Myeloma
Preliminary Assessment of [18F]BL40 in PET/CT Scans
CXCR4 is type of receptor that has been detected in more than twenty different subtypes of cancers. Most of these cancers are associated with negative symptoms that worsen over time resulting in great disability and poor…
- Conditions
- Diffuse Large B-cell Lymphoma, Multiple Myeloma, Mantle Cell Lymphoma, Marginal Zone Lymphoma
- Trial name
- NCT06224309
- Testing
- 18F-BL40 PET/CT, 18F-FDG PET/CT, Routine Blood Draw - Phase 1 only
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- British Columbia Cancer Agency
Breast Cancer, Lung Cancer
Investigating the Effects of Atezolizumab in People Whose Tumour DNA or RNA Indicates Possible Sensitivity
This study will investigate the effects of atezolizumab on select cancer types in people whose analysis of tumour DNA and RNA indicates they may be sensitive to atezolizumab.
- Conditions
- Breast Cancer, Lung Cancer, Gastrointestinal Cancer, Genitourinary Cancer
- Trial name
- CAPTIV-8 (NCT04273061)
- Testing
- Atezolizumab
- Where
- 2 sites in Canada
- Volunteers
- 50 people
- Sponsor
- British Columbia Cancer Agency
Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma
Using Tumour DNA and Proteins to Better Understand How Pancreatic Cancer Responds to Treatment
The goal of this study is to learn if the genetic information and proteins from tumours can help treat pancreatic ductal adenocarcinoma (PDAC).
- Conditions
- Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma, Borderline Resectable Pancreatic Ductal Adenocarcinoma, Locally Advanced Pancreatic Ductal Adenocarcinoma
- Trial name
- ACCELERATE (NCT06574620)
- Testing
- Genetic testing, Optional biopsy, Tissue collection
- Where
- Canada
- Volunteers
- 200 people
- Sponsor
- British Columbia Cancer Agency
Pancreatic Ductal Adenocarcinoma (PDAC), Hand Grip Strength
Using Strength Tests to Better Understand How Pancreatic Cancer Affects Muscle Mass and Quality of Life
The goal of this clinical trial is to measure hand grip strength in adults with pancreatic ductal adenocarcinoma (PDAC). The main questions it aims to answer are: Is it feasible to measure hand grip strength as part of a clinic…
- Trial name
- PanFit (NCT07255001)
- Testing
- Hand grip strength assessments using a dynamometer
- Where
- Canada
- Volunteers
- 50 people
- Sponsor
- British Columbia Cancer Agency
Completed, with results posted
All 8Prostate Cancer, Prostate Cancer Metastatic
MSG Use With 18F-DCFPyL PET/CT Imaging
18F-DCFPyL is an agent that binds to prostate specific membrane antigen (PSMA). Due to high levels of PSMA in prostate cancer, treatments targeting PSMA have been developed to deliver therapy to these specific target cells.
- Conditions
- Prostate Cancer, Prostate Cancer Metastatic, Prostatic Neoplasm
- Trial name
- NCT03693742
- Testing
- 18F-DCFPyL PET/CT scan, MSG drink
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- British Columbia Cancer Agency
Breast Cancer
A Randomized Trial of Letters From Family Physicians to Encourage Screening Mammography in Overdue Women
A randomized, double-blinded study conducted in British Columbia, Canada, where there is a publicly funded, organized screening program and screening mammography is recommended at 24-month intervals.
- Trial name
- NCT02660788
- Testing
- Standard Reminder Postcard, Family Physician Reminder Letter
- Where
- Canada
- Volunteers
- 5,498 people, healthy volunteers welcome
- Sponsor
- British Columbia Cancer Agency
Prostate Cancer
High Dose Rate Prostate Brachytherapy: Dose Escalation to Dominant Intra-prostatic Nodule
This study will investigate the feasibility of using technology of ultrasound guided HDR brachytherapy to focally increase dose to regions within the prostate that are heavily infiltrated with cancer.
- Trial name
- Dosepainting (NCT01605097)
- Testing
- HDR interstitial brachytherapy
- Where
- Canada
- Volunteers
- 26 people
- Sponsor
- British Columbia Cancer Agency
Prostate Cancer, Interstitial Radiation
CT-validation of Ultrasound Based Planning for High Dose Rate (HDR) Prostate Brachytherapy Using Vitesse
High Dose Rate (HDR) temporary prostate brachytherapy offers a precise form of dose escalation for prostate cancer. Needles are placed, the position is confirmed and treatment is delivered.
- Conditions
- Prostate Cancer, Interstitial Radiation, High Dose Rate Brachytherapy, Ultrasound-based Planning Compared to CT-based Planning
- Trial name
- Vitesse (NCT01248741)
- Testing
- HDR prostate brachytherapy
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- British Columbia Cancer Agency
Metastatic Colorectal Cancer
Phase II Study of Perindopril and Regorafenib in mCRC
The purpose of this study is to find out what effects the combination of regorafenib and perindopril has on hand-foot skin reaction (HFSR), on high blood pressure (hypertension) and on any other types of side-effects and compare…
- Trial name
- PARICCA (NCT02651415)
- Testing
- Regorafenib, Perindopril
- Where
- Canada
- Volunteers
- 12 people
- Sponsor
- British Columbia Cancer Agency